menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Immunization Against Influenza in Older Adults: Reviewing the ACIP Recommendations

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Are you up to date on the latest recommendations for influenza vaccination in older adults from the CDC’s Advisory Committee on Immunization Practices?

Please See

Important Safety Information

  • Sponsored by

  • Overview

    It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.

    References:
    1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
    2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.

    USA-FLUD-22-0056 December 2022

  • FLUAD® and FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

    IMPORTANT SAFETY INFORMATION

    INDICATIONS AND USAGE
    FLUAD® and FLUAD® QUADRIVALENT are inactivated influenza vaccines indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD® and FLUAD® QUADRIVALENT are approved for use in persons 65 years of age and older.

    This indication is approved under accelerated approval based on the immune response elicited by FLUAD® and FLUAD® QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Data demonstrating a decrease in influenza disease after vaccination with FLUAD® or FLUAD® QUADRIVALENT is not available.

    CONTRAINDICATIONS
    Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

    WARNINGS AND PRECAUTIONS
    If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD® or FLUAD® QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

    Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

    The immune response to FLUAD® or FLUAD® QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

    Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD® and FLUAD® QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

    ADVERSE REACTIONS
    FLUAD® administered by needle and syringe:
    The most common (≥10%) local (injection site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%).

    The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (13%).

    FLUAD® QUADRIVALENT administered by needle and syringe:
    The most common (≥ 10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

    Other adverse events may occur. For a comprehensive list of local and systemic adverse reactions, please see full prescribing information.

    To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1- 855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov

    Before administration, please see the full Prescribing Information for FLUAD® or FLUAD® QUADRIVALENT.

    FLUAD® and FLUAD® QUADRIVALENT are registered trademarks of Seqirus UK Limited or its affiliates. 

Schedule3 Feb 2023